Eprinomectin (Eprinex)

Eprinomectin is a semisynthetic macrocyclic lactone antiparasitic compound belonging to the avermectin class, distinguished by its unique pharmacokinetic profile that permits use in lactating dairy cattle with no milk withdrawal requirement. This breakthrough characteristic made eprinomectin the first endectocide approved for use in dairy cattle during lactation in the United States, addressing a significant unmet need in dairy production where parasite control options had been limited by concerns about drug residues in milk. The compound was developed through chemical modification of avermectin B1, resulting in a molecule that retains potent antiparasitic activity while demonstrating preferential partitioning away from milk, enabling the zero-day milk discard interval that defines its role in dairy parasite management.

The mechanism of action of eprinomectin mirrors that of other macrocyclic lactones, involving high-affinity binding to glutamate-gated chloride ion channels found specifically in invertebrate nerve and muscle cells. This binding results in increased membrane permeability to chloride ions, causing hyperpolarization, paralysis, and subsequent death of susceptible parasites. The selectivity for invertebrate-specific receptors provides an excellent safety margin in mammalian hosts, as these binding sites are absent in mammals. Eprinomectin demonstrates exceptional potency against a broad spectrum of nematodes (roundworms) and arthropod parasites (lice, mites, grubs), functioning as a true endectocide that addresses both internal and external parasite challenges with a single application.

Eprinomectin is commercially available in two primary formulation types designed for different treatment strategies. The original pour-on formulation (Eprinex, 0.5% or 5 mg/mL eprinomectin) is applied topically along the backline of cattle and provides effective treatment with conventional duration of activity. More recently, an extended-release injectable formulation (LongRange, 5% or 50 mg/mL eprinomectin) was introduced, providing up to 100-150 days of persistent activity against certain parasites through a unique polymer matrix that allows slow drug release from the injection site. This extended-release technology represents a significant advancement in parasite control strategy, potentially reducing the number of treatments required during a grazing season.

Regulatory approval of eprinomectin encompasses both dairy and beef cattle, with specific labeling for each formulation type. The pour-on formulation carries a zero-day meat withdrawal and zero-hour milk withhold for cattle, making it the most flexible option for dairy operations where milk must be marketed continuously. The extended-release injectable formulation carries a 48-day meat withdrawal but is not approved for use in female dairy cattle 20 months of age or older, or in calves to be processed for veal. These distinctions reflect the different pharmacokinetic profiles of the formulations and their respective tissue residue depletion characteristics. Producers must carefully match product selection to their production system and marketing requirements.

Eprinomectin pour-on is FDA-approved for the treatment and control of an extensive range of gastrointestinal nematodes in beef and dairy cattle. Labeled indications include control of adult and immature stages of Ostertagia ostertagi (including inhibited fourth-stage larvae, which represent a significant cause of production losses in cattle), Haemonchus placei, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Nematodirus helvetianus, Oesophagostomum radiatum, Bunostomum phlebotomum, and Strongyloides papillosus. The comprehensive coverage of economically important gastrointestinal parasites makes eprinomectin suitable as a primary deworming agent across diverse cattle production systems.

Respiratory parasites and tissue-dwelling nematodes are also within the spectrum of eprinomectin activity. The product is effective against lungworms (Dictyocaulus viviparus) at all stages present in the lung tissue, providing important protection against the respiratory compromise and production losses associated with parasitic bronchitis. Eyeworms (Thelazia spp.) affecting the conjunctival sac and associated structures are controlled by eprinomectin treatment. Additionally, cattle grubs—the larval stages of Hypoderma bovis and H. lineatum (warble flies or heel flies)—are effectively eliminated, preventing the tissue damage, hide damage, and potential complications associated with grub migration through host tissues.

Ectoparasite control with eprinomectin encompasses several economically significant external parasites affecting cattle. The product demonstrates efficacy against sucking lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus) and biting lice (Bovicola bovis), parasites that cause hide damage, blood loss, irritation, and reduced production efficiency. Chorioptic mange mites (Chorioptes bovis) and sarcoptic mange mites (Sarcoptes scabiei var. bovis) are controlled, addressing these intensely pruritic conditions that can significantly impair cattle welfare and productivity. The combined endoparasite and ectoparasite activity allows comprehensive parasite management with a single product application.

The extended-release injectable formulation (LongRange) provides persistent efficacy against key parasites for extended periods, fundamentally changing strategic treatment approaches. This formulation offers up to 100 days of persistent activity against Ostertagia ostertagi and Cooperia punctata, up to 150 days against Dictyocaulus viviparus, and effective treatment of established infections of multiple nematode species at the time of administration. This extended protection enables season-long parasite control with a single pre-turnout treatment in many management systems, reducing the need for mid-season treatments and minimizing cattle handling requirements.

The zero milk withdrawal feature of eprinomectin pour-on addresses the unique challenges of parasite control in lactating dairy cattle. Prior to eprinomectin availability, dairy producers faced limited options, as most effective anthelmintics required extended milk discard periods that created economic losses and logistical challenges. The ability to treat lactating cows without milk loss enables integration of strategic deworming into dairy herd health programs, targeting treatment to periods of maximum benefit such as freshening, dry-off, or grazing season while maintaining continuous milk marketing. This capability has made eprinomectin the predominant parasite control agent in dairy cattle production systems throughout North America and other regions.

The standard dose of eprinomectin pour-on for cattle is 500 micrograms per kilogram of body weight (0.5 mg/kg), administered topically along the midline of the back. Using the 0.5% formulation (5 mg/mL), this equates to 1 mL of product per 10 kg (22 pounds) of body weight. The product should be applied in a narrow strip extending from the withers to the tailhead, allowing the formulation to spread across the animal's back through normal movement and grooming behavior. Accurate body weight estimation is essential; the use of livestock scales or breed-specific weight tapes ensures appropriate dosing and minimizes the risk of underdosing, which can contribute to treatment failure and anthelmintic resistance development.

Application conditions significantly influence the efficacy of pour-on formulations. Eprinomectin pour-on should be applied to dry cattle, as wet hair coats can impair absorption and reduce drug bioavailability. Treatment should be avoided if rain is expected within several hours of application, as precipitation can wash product from the hair coat before adequate absorption occurs. Animals should not have access to ponds, streams, or other water bodies immediately following treatment to prevent both reduced efficacy from wash-off and potential environmental contamination. The applicator gun or measuring device should be calibrated to deliver accurate volumes, and equipment should be cleaned between uses to prevent cross-contamination.

The extended-release injectable formulation (LongRange) is administered by subcutaneous injection in the front of the shoulder at a dose of 1 mg eprinomectin per kilogram of body weight. Using the 5% formulation (50 mg/mL), this corresponds to 1 mL per 50 kg (110 pounds) of body weight. The injection site in the neck region minimizes potential for carcass trim losses from injection site lesions. Proper injection technique—using 16- to 18-gauge needles of appropriate length, tenting the skin to ensure subcutaneous placement, and limiting injection volume to no more than 10 mL per site—optimizes product distribution and minimizes local reactions. The extended-release formulation should not be administered by any route other than subcutaneous injection.

Treatment timing for both formulations should be strategically planned based on parasite epidemiology, production goals, and environmental conditions. For the pour-on formulation, treatment at housing in fall eliminates accumulated summer parasite burdens, treatment at spring turnout reduces initial pasture contamination, and mid-season treatments address ongoing parasite challenge during the grazing season. For the extended-release injectable, the extended duration of activity allows single pre-turnout treatment to provide season-long protection in many situations, particularly valuable in operations where cattle handling is difficult or infrequent.

For cattle grub control, treatment timing relative to grub migration is critical to avoid host-parasite reactions. Treatment should occur after heel fly activity has ceased but before grubs have migrated to the esophageal or spinal regions—typically November through February in most of North America. Treating during active migration can result in adverse reactions from dying larvae in sensitive tissues. The extended-release injectable formulation, when administered before the grazing season, may prevent grub establishment altogether by killing early larval stages before significant migration occurs.

Withdrawal times differ substantially between formulations and must be strictly observed. Eprinomectin pour-on carries zero-day meat withdrawal and zero-hour milk withhold, permitting use immediately before slaughter or during continuous milk marketing. The extended-release injectable formulation requires a 48-day meat withdrawal and is not approved for use in female dairy cattle 20 months of age or older, male and female dairy cattle intended for veal production, or any cattle less than 3 months of age. These differences necessitate careful product selection based on the production system and marketing timeline for treated animals.

Eprinomectin demonstrates excellent tolerance in cattle when administered according to label directions, consistent with the favorable safety profile characteristic of the macrocyclic lactone class. The wide margin of safety derives from the high selectivity of eprinomectin for invertebrate glutamate-gated chloride channels, which are absent in mammalian species. Clinical trials supporting FDA approval and extensive post-marketing experience have confirmed that adverse effects are uncommon and generally mild when they do occur. The safety profile of the pour-on formulation in lactating dairy cattle specifically was a critical factor in its approval for use without milk withdrawal, as regulators required demonstration of negligible milk residues combined with maternal tolerance.

Transient skin reactions at the application site may occur following pour-on administration, particularly in animals with pre-existing skin irritation or sensitivity. These reactions typically manifest as mild erythema (redness), temporary hair coat changes, or localized swelling that resolves without intervention within several days. The organic solvent vehicle in pour-on formulations can contribute to these local effects. In most cases, application site reactions do not affect animal behavior, appetite, or production, and no specific treatment is required. Animals with known skin sensitivities or active dermatological conditions may be at increased risk for local reactions.

The extended-release injectable formulation may cause injection site reactions including transient swelling, firmness, or granuloma formation at the injection site. These reactions reflect the tissue response to both the drug formulation and the extended-release polymer matrix that enables prolonged drug release. Swelling at the injection site may persist for several weeks following administration but typically resolves without treatment. Proper injection technique—subcutaneous placement in the recommended site, appropriate needle selection, and adherence to maximum volume per site—minimizes the incidence and severity of injection site reactions. In cattle destined for slaughter, injection site lesions may require trimming, emphasizing the importance of the 48-day withdrawal period.

Systemic adverse effects from eprinomectin are rare at recommended doses. Neurological signs including depression, ataxia, and mydriasis have been reported rarely, typically in association with accidental overdose or administration to very young animals with incompletely developed blood-brain barriers. The blood-brain barrier normally excludes macrocyclic lactones from the central nervous system, but this protection may be compromised in neonates or animals with certain conditions affecting barrier integrity. If neurological signs occur, supportive care is indicated, as there is no specific antidote for avermectin intoxication. Most affected animals recover fully with supportive management.

Host-parasite reactions following treatment of heavily parasitized animals deserve recognition as potential complications distinct from direct drug toxicity. When treating cattle for cattle grubs, the death of larvae migrating through or dwelling in sensitive tissues can provoke inflammatory reactions. Dying grubs in the esophageal region may cause swelling that produces bloat symptoms, while those near the spinal column may cause neurological signs including hindquarter weakness or paralysis. These reactions are minimized by treating during the recommended treatment window (November-February in most of North America) when grubs have not yet reached critical anatomical locations. In heavily parasitized animals treated outside this window, close monitoring for complications is warranted, and treatment of smaller groups rather than entire herds allows for more attentive observation and prompt intervention if problems arise.

The extended-release injectable formulation of eprinomectin (LongRange) is specifically contraindicated for use in female dairy cattle 20 months of age or older, reflecting the extended tissue residence of this formulation and absence of established milk withdrawal data. This restriction applies regardless of current lactation status—replacement dairy heifers over 20 months of age and dry dairy cows are both excluded from use. The standard pour-on formulation does not carry this restriction and may be used in lactating dairy cattle with its established zero-hour milk withhold. Dairy producers must carefully verify which formulation is being considered to ensure compliance with these species and production-class restrictions.

Neither eprinomectin formulation is approved for use in calves intended for veal production. The extended-release injectable specifically excludes dairy cattle intended for veal processing at any age, while both formulations require attention to the relatively young slaughter age of veal calves in relation to tissue residue depletion. Veal producers requiring parasite control should select products specifically approved for their production system with withdrawal times compatible with the expected slaughter timeline. Consultation with a veterinarian familiar with veal production can help identify appropriate treatment options.

Eprinomectin should not be administered to animals with known hypersensitivity to avermectin class compounds. While true allergic reactions are rare, animals that have demonstrated adverse reactions to eprinomectin, ivermectin, doramectin, moxidectin, or related compounds should not receive additional treatments with any macrocyclic lactone. Cross-reactivity among drugs within this class has been documented. A thorough treatment history should be obtained, and alternative anthelmintic classes should be selected for animals with documented macrocyclic lactone sensitivity.

Use of the extended-release injectable formulation in cattle less than 3 months of age is contraindicated per label directions. Young animals may have incompletely developed blood-brain barriers that increase susceptibility to central nervous system effects, and the extended drug release from this formulation prolongs the exposure period. The pour-on formulation does not carry a specific minimum age restriction but should be used with appropriate caution in very young animals. When parasite control is necessary in young calves, accurate weight-based dosing and careful post-treatment monitoring are essential. For both formulations, severely debilitated, stressed, or diseased animals warrant careful evaluation of the risk-benefit ratio before treatment, as compromised animals may demonstrate altered drug handling or increased susceptibility to adverse effects.

Concurrent administration of eprinomectin with other macrocyclic lactone anthelmintics should be avoided to prevent cumulative toxicity from drug class overlap. The macrocyclic lactones—including ivermectin, doramectin, moxidectin, and selamectin—share a common mechanism of action and similar pharmacokinetic behavior, making combination use potentially hazardous. This interaction concern is relevant when animals are moved between operations with different deworming programs, when animals receive treatment without adequate treatment history, or when combination products containing macrocyclic lactones are used without recognition of all active ingredients. Adequate intervals between treatments with different macrocyclic lactones should be observed, with specific timing dependent on the duration of activity of each product.

Ionophore antibiotics used in cattle production for growth promotion and coccidiosis control may interact with macrocyclic lactones through effects on P-glycoprotein transport systems. Ionophores including monensin, lasalocid, and similar compounds are commonly incorporated in cattle feeds and mineral supplements. P-glycoprotein functions as an efflux pump that normally limits macrocyclic lactone penetration into the central nervous system, and ionophore-mediated interference with this protective mechanism could theoretically increase the risk of neurotoxicity. While clinical problems from this interaction are uncommon when both drug classes are used at labeled doses, concurrent use warrants awareness and appropriate animal monitoring. This interaction is particularly relevant when the extended-release eprinomectin formulation is used, as the prolonged drug exposure increases the duration of potential interaction.

Other P-glycoprotein inhibitors beyond ionophores may affect eprinomectin disposition, although specific interactions in cattle have not been extensively characterized. Drugs including ketoconazole, itraconazole, quinidine, and cyclosporine are recognized P-glycoprotein inhibitors, and concurrent use with macrocyclic lactones warrants caution. While these specific combinations are uncommon in routine cattle practice, they may be relevant in intensive care situations, during treatment of valuable breeding stock receiving multiple medications, or in situations involving concurrent disease treatment. Consultation with a veterinarian regarding potential interactions is advisable when eprinomectin treatment is planned for animals receiving other medications.

Vaccination programs are commonly conducted concurrently with deworming treatments during cattle processing events, and potential interactions merit consideration. Clinical studies and field experience generally indicate that eprinomectin does not significantly interfere with immune responses to common cattle vaccines. However, the theoretical potential for immunomodulatory effects of macrocyclic lactones has prompted some practitioners to recommend separating treatment and vaccination by 48-72 hours when logistically feasible. When concurrent administration is necessary for practical management—such as during processing of cattle that will not be handled again soon—the benefits of comprehensive health management typically outweigh theoretical interaction concerns, and both procedures may proceed simultaneously.

Human safety precautions during eprinomectin handling and administration minimize occupational exposure risk. The pour-on formulation vehicle is designed to enhance drug penetration through the skin, making human dermal exposure a relevant concern. Waterproof gloves should be worn during product handling and application, and direct skin contact should be avoided. In case of accidental skin exposure, the affected area should be washed promptly with soap and water. Eye protection is recommended, as ocular exposure to the formulation can cause irritation; if eye contact occurs, eyes should be flushed thoroughly with clean water. Individuals with known sensitivity to avermectin compounds should avoid product handling. The extended-release injectable formulation poses additional sharps hazards, and standard needlestick precautions apply.

Food safety considerations require strict attention to withdrawal time compliance, particularly given the different requirements between eprinomectin formulations. The pour-on formulation's zero-day meat withdrawal and zero-hour milk withhold reflect the unique pharmacokinetic profile of this formulation specifically and cannot be extrapolated to other macrocyclic lactones. The extended-release injectable requires a 48-day meat withdrawal, and treated animals must be clearly identified and tracked to prevent premature slaughter. Accurate treatment records—including date, product identification, animal identification, and calculated withdrawal dates—are essential components of residue avoidance programs. Producers should verify withdrawal times against current product labeling, as requirements may change with label updates.

Environmental stewardship considerations apply to eprinomectin use given its toxicity to non-target invertebrates and aquatic organisms. Residues excreted in feces of treated cattle can affect dung beetle populations and other coprophagous invertebrates important to pasture ecology. Pour-on formulations may pose additional environmental risk through run-off into water bodies, where aquatic invertebrates are particularly sensitive to macrocyclic lactone toxicity. Treatment should be avoided when heavy rain is expected, and recently treated cattle should not have direct access to streams, ponds, or other surface water. Strategic, targeted treatment approaches—rather than routine prophylactic treatment of all animals—reduce overall environmental drug loading while maintaining effective parasite control.

Anthelmintic resistance management represents a critical consideration for preserving eprinomectin efficacy for future use. Resistance to macrocyclic lactones has been documented in multiple nematode species affecting cattle globally, and selection pressure from widespread drug use continues to drive resistance development. Practices supporting resistance management include accurate dosing based on actual body weights, avoiding underdosing that allows resistant parasites to survive and reproduce, maintaining refugia through selective treatment strategies that leave some animals untreated, rotating among anthelmintic classes with different mechanisms of action, and monitoring treatment efficacy through fecal egg count reduction tests. When reduced efficacy is suspected, consultation with a veterinarian or parasitologist can guide adjustments to the parasite control program.

Proper product selection requires matching the appropriate eprinomectin formulation to the specific production system and animal class. The pour-on and extended-release injectable formulations are not interchangeable—they have different doses, different routes of administration, different durations of activity, and critically different use restrictions regarding dairy cattle. Selecting the wrong formulation could result in either regulatory violations (if the extended-release injectable is used in dairy cattle) or suboptimal parasite control (if the pour-on is used when extended-duration protection is desired). Careful attention to product labeling and confirmation of appropriate use for the intended animal class prevents errors that could have economic or regulatory consequences.

Eprinomectin products should be stored according to manufacturer specifications to ensure product integrity and efficacy throughout the labeled shelf life. The pour-on formulation should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from direct sunlight and extreme temperature fluctuations. The extended-release injectable formulation may have specific storage requirements related to the extended-release matrix technology; label directions should be consulted and followed precisely. Both formulations should be protected from freezing, which can compromise product consistency and efficacy. Storage in climate-controlled areas rather than uninsulated barns or vehicles subject to temperature extremes helps maintain product quality.

Multi-dose container handling for the extended-release injectable formulation requires attention to aseptic technique to prevent contamination. The rubber stopper should be disinfected before each needle entry, and needles should be changed frequently rather than using a single needle for multiple entries. Contamination of the product with organic debris or microorganisms can cause injection site complications in treated animals and may affect product stability. The contents of multi-dose vials should be used within the timeframe specified on the product label once the vial is first entered. Recording the opening date on multi-dose containers supports appropriate use timelines. Pour-on formulations are typically used from larger containers through calibrated applicator guns; these application systems should be cleaned and maintained according to manufacturer recommendations.

Disposal of eprinomectin products and containers must comply with federal, state, and local environmental regulations. Eprinomectin is highly toxic to fish and aquatic invertebrates, and improper disposal could cause significant environmental harm. Empty pour-on containers should be triple-rinsed before disposal, with rinsate applied to a land application area away from water sources. Containers should be rendered non-reusable by puncturing or crushing. The extended-release injectable generates sharps waste (needles) that must be disposed of in designated sharps containers through appropriate medical waste channels. Unused or expired product should be disposed of through veterinary pharmaceutical return programs, agricultural chemical collection programs, or hazardous waste collection services. Product should never be disposed of by pouring into drains, water bodies, or areas where groundwater contamination could occur.

The distinction between dairy and beef cattle production systems represents the most significant consideration for eprinomectin product selection and use. For dairy breeds—Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and others managed for milk production—the pour-on formulation is the appropriate choice due to its zero-hour milk withhold that permits continuous milk marketing. The extended-release injectable formulation is explicitly not approved for female dairy cattle 20 months of age or older, making it unsuitable for the milking herd regardless of current lactation status. Dairy steers being raised for beef are not subject to dairy restrictions and may receive either formulation with appropriate withdrawal time observance.

Beef cattle production systems have greater flexibility in eprinomectin formulation selection. Both the pour-on and extended-release injectable formulations are approved for use in beef cattle of appropriate ages, and product choice depends on management goals and handling logistics. The extended-release injectable may be particularly valuable in extensive grazing operations where cattle handling is infrequent or difficult, as single pre-turnout treatment can provide season-long protection. Cow-calf operations can utilize the extended-release product in breeding cows and bulls with attention to the 48-day meat withdrawal for any animals that might be culled during the protection period.

Age and weight considerations influence treatment decisions across production types. The extended-release injectable is contraindicated in cattle less than 3 months of age, while the pour-on formulation has no specific minimum age restriction but warrants careful use in very young animals. Accurate weight determination is essential regardless of formulation, as both products are dosed on a weight basis and young or small animals have less margin for dosing error. Lightweight animals requiring small doses should be dosed with care using appropriately calibrated application equipment. Very young calves nursing treated dams may receive some drug exposure through milk, though eprinomectin's low milk partitioning minimizes this concern.

Breed-specific sensitivities to macrocyclic lactones comparable to those documented in certain dog breeds have not been established in cattle. However, individual animal variation in drug response does occur, and any animal demonstrating adverse reactions following treatment should be identified and excluded from future treatment with macrocyclic lactones. Body condition affects the pharmacokinetics of lipophilic drugs like eprinomectin; animals with significant fat cover may demonstrate prolonged tissue residence compared to leaner animals. While labeled withdrawal times incorporate appropriate safety margins, awareness of these factors supports informed management decisions, particularly for animals that may be marketed near the end of withdrawal periods.

Within the macrocyclic lactone class, several alternative compounds offer comparable broad-spectrum antiparasitic activity with differences that may influence product selection for specific situations. Ivermectin (Ivomec) was the original avermectin introduced for livestock use and remains widely available in injectable, pour-on, and oral formulations, though it requires milk discard when used in dairy cattle. Doramectin (Dectomax) offers similar spectrum and formulation options but also lacks approval for use in lactating dairy cattle. Moxidectin (Cydectin) is a milbemycin with extended duration of activity and potential advantages against some ivermectin-resistant parasites; pour-on and injectable formulations are available. Eprinomectin remains unique among macrocyclic lactones for its zero milk withdrawal pour-on formulation approved for lactating dairy cattle.

Anthelmintics from different chemical classes provide options for resistance management and may be preferred when macrocyclic lactone resistance is suspected. Benzimidazoles including fenbendazole (Safe-Guard, Panacur) and albendazole (Valbazen) offer broad-spectrum nematode control through inhibition of microtubule formation, a mechanism distinct from macrocyclic lactones. Levamisole (Levasole, Prohibit) acts through nicotinic receptor agonism causing spastic paralysis. These alternative classes can be used in rotation with macrocyclic lactones to reduce selection pressure or in combination with macrocyclic lactones as part of strategies designed to manage resistant parasite populations. For dairy cattle, each alternative product's milk withdrawal time must be considered in the treatment decision.

Combination products may incorporate eprinomectin or other macrocyclic lactones with additional antiparasitic agents to address broader parasite spectrum or enhance efficacy against resistant populations. Combinations with benzimidazoles provide complementary mechanisms of action, while combinations with flukicides address concurrent liver fluke infections in areas where flukes are endemic. When selecting combination products, attention to the spectrum of activity, withdrawal times for all active components, and specific approved uses ensures appropriate application. The economic and management considerations of combination products versus sequential treatment with single-active products vary by operation and should be evaluated based on individual farm circumstances, parasite challenges, and handling logistics.